Evidence map›Paper›PMID 42010672›Full record

ReviewNeurological research and practice2026

Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions.

Eva Schaeffer, Jos Steffen Becktepe, Kathrin Brockmann, Carsten Eggers, Eileen Gülke, Elke Kalbe, Tim W Rattay, Lars Tönges, Tobias Warnecke, Kirsten E Zeuner and 1 more

Abstract readReview
In one paragraph

Review in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eva SchaefferDepartment of Neurology, Christian-Albrechts-University of Kiel, UKSH Campus Kiel Arnold-Heller-Straße 3, Haus D, 24105, Kiel, Germany. eva.schaeffer@uksh.de.ORCID http://orcid.org/0000-0002-0792-4383
Jos Steffen BecktepeAugust-Bier-Klinik, Specialist clinic for neurology and neurorehabilitation, Bad Malente-Gremsmühlen, Germany.
Kathrin BrockmannDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tuebingen, Hoppe Seyler‑Strasse 3, 72076, Tuebingen, Germany.
Carsten EggersKnappschaft Kliniken Bottrop, Department of Neurology, Bottrop, Germany.
Eileen GülkeHealth and Human Sciences, Macquarie Medical School and Macquarie University Centre for Parkinsons Disease Research, Macquarie University, Sydney, NSW, Australia.
Elke KalbeMedical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tim W RattayDepartment of Neurology, Christian-Albrechts-University of Kiel, UKSH Campus Kiel Arnold-Heller-Straße 3, Haus D, 24105, Kiel, Germany.
Lars TöngesDepartment of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
Tobias WarneckeDepartment of Neurology and Neurorehabilitation, Klinikum Osnabrück - Academic Teaching Hospital of the University of Münster, Münster, Germany.
Kirsten E ZeunerDepartment of Neurology, Christian-Albrechts-University of Kiel, UKSH Campus Kiel Arnold-Heller-Straße 3, Haus D, 24105, Kiel, Germany.
Daniela BergDepartment of Neurology, Christian-Albrechts-University of Kiel, UKSH Campus Kiel Arnold-Heller-Straße 3, Haus D, 24105, Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the fastest growing neurological disorder worldwide and, together with other movement disorders, belongs to a group of chronic neurological conditions associated with a substantial burden for affected individuals, caregivers, and healthcare systems. Despite significant advances in symptomatic treatment, disease-modifying therapies remain unavailable, shifting increasing attention toward prevention as a key therapeutic strategy. In this narrative we primarily focus on PD, as the epidemiologically most challenging condition and the one for which the most comprehensive evidence base for preventive strategies has been established. Preventive approaches relevant to other movement disorders are briefly discussed to highlight other promising targets requiring further investigations. In recent years major progress has been achieved in the identification of modifiable factors relevant for primary prevention of PD. Well-supported factors include physical activity, adherence to a Mediterranean diet, and caffeine or tea consumption as protective factors, as well as pesticide exposure as a relevant risk factor. Advances in early and prodromal diagnosis of PD have opened new perspectives for secondary prevention. Earlier identification of individuals at risk may enable timely interventions aimed at attenuating early disease progression. However, despite this progress, the systematic implementation of early therapeutic interventions in the prodromal phase remains limited. Evidence is sparse and largely indirect, mainly inferred from later disease onset associated with physical activity and dietary patterns. Similarly, although early diagnosis and treatment of cognitive impairment are clearly recommended by clinical guidelines, they remain insufficiently integrated into routine clinical care. Finally, tertiary prevention strategies are supported by a broad evidence base. Multidisciplinary rehabilitative care models have demonstrated clear benefits in preventing complications, maintaining daily functioning and quality of life. While such rehabilitative approaches are widely implemented, the strong evidence supporting moderate- to high-intensity physical exercise remains insufficiently translated into routine practice. Looking ahead, a key goal for the coming decades is the development of personalized prevention strategies, including beyond other insights into gene-environment interactions and the integration of multi-omics data to tailor interventions to individual risk profiles. Such approaches hold promise to maximize preventive efficacy and reduce the overall burden of PD and related movement disorders.

Indexed as

Early diagnosisMovement disordersParkinson’s diseasePreventionRehabilitationRisk factors

Identifiers

PMID42010672
PMCPMC13097574

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.